Edwards Lifesciences Co. (NYSE:EW) CEO Bernard J. Zovighian Sells 6,164 Shares

Edwards Lifesciences Co. (NYSE:EW) CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Edwards Lifesciences Trading Down 0.1 %

EW opened at $68.49 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market cap of $40.26 billion, a P/E ratio of 9.83, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a fifty day moving average price of $72.03 and a two-hundred day moving average price of $70.35.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. Vega Investment Solutions bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $29,000. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth about $30,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the 4th quarter worth about $30,000. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group lifted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Citigroup lifted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Truist Financial reiterated a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Finally, Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.